{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:25:51Z","timestamp":1795026351384,"version":"4.10.2"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To evaluate outcomes with simultaneous administration of mifepristone and misoprostol for medical abortion at 63 days of gestation or less in the year after its implementation in a British clinic system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using deidentified data from the electronic booking and complications databases and medical records of women who underwent medical abortion at British Pregnancy Advisory Service. Our primary outcome was treatment success with simultaneous dosing compared with a regimen with a 24- to 48-hour interval between medications. We defined success as complete abortion without surgical evacuation and without continuing pregnancy. To assess relative regimen effectiveness while accounting for self-assignment to simultaneous or interval dosing, we modeled the probability of treatment success using logistic regression with propensity score adjustment for demographic and clinical characteristics. Secondary outcomes were reasons for abortion failure and clinically significant adverse events (hospital admission, blood transfusion, intravenous antibiotic administration).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of 28,901 women treated between May 2015 and April 2016, 85% chose simultaneous dosing. Overall success rates were high with both regimens but lower with simultaneous than with interval dosing (94.5% vs 97.1%, respectively, adjusted relative risk 0.973, 95% CI 0.967\u20130.979). For both regimens, success rates were lower at higher gestational ages, but the relative effectiveness of simultaneous dosing did not vary significantly with gestational age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.268). Surgical intervention rates for continuing pregnancy were lowest at 49 days of gestation or less (1.4% simultaneous vs 0.2% interval,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001) and highest at 57\u201363 days of gestation (5.0% and 2.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.001). The rate of clinically significant adverse events was 0.2% and did not differ by regimen (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.972).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Simultaneous administration of mifepristone and misoprostol is 97% as effective as a 24- to 48-hour interval at all gestational ages 63 days or less with no increase in the risk of clinically significant adverse events. Pragmatic use of simultaneous dosing is reasonable given the small difference in effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000002536","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T18:42:17Z","timestamp":1520793737000},"page":"635-641","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Simultaneous Compared With Interval Medical Abortion Regimens Where Home Use Is Restricted"],"prefix":"10.1097","volume":"131","author":[{"given":"Patricia A.","family":"Lohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail R. A.","family":"Aiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261118","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.contraception.2015.06.011","article-title":"If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion","volume":"92","author":"Gold","year":"2015","journal-title":"Contraception"},{"key":"R2-20261118","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2471\/BLT.10.084046","article-title":"Comparative effectiveness, safety and acceptability of medical abortion at home and in a clinic: a systematic review","volume":"89","author":"Ngo","year":"2011","journal-title":"Bull World Health Organ"},{"key":"R6-20261118","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/01.AOG.0000115511.14004.19","article-title":"Routine follow-up visits after first-trimester induced abortion","volume":"103","author":"Grossman","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R7-20261118","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2307\/2136257","article-title":"Acceptability of medical abortion in early pregnancy","volume":"27","author":"Winikoff","year":"1995","journal-title":"Fam Plann Perspect"},{"key":"R8-20261118","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1028-4559(09)60252-7","article-title":"Concurrent use of mifepristone and misoprostol for early medical abortion","volume":"45","author":"Li","year":"2006","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R9-20261118","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.contraception.2005.12.011","article-title":"Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion","volume":"73","author":"Kapp","year":"2006","journal-title":"Contraception"},{"key":"R10-20261118","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/01.AOG.0000258298.35143.d2","article-title":"Medical Abortion at the Same Time (MAST) Study Trial Group. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial","volume":"109","author":"Creinin","year":"2007","journal-title":"Obstet Gynecol"},{"key":"R11-20261118","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00404-011-1881-2","article-title":"Simultaneous administration of mifepristone and misoprostol for early termination of pregnancy: a randomized controlled trial","volume":"283","author":"Goel","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R12-20261118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tjog.2010.09.002","article-title":"Simultaneous use of mifepristone and misoprostol for early pregnancy termination","volume":"50","author":"Li","year":"2011","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R14-20261118","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.contraception.2014.09.009","article-title":"Can women determine the success of early medical termination of pregnancy themselves?","volume":"91","author":"Cameron","year":"2015","journal-title":"Contraception"},{"key":"R15-20261118","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.contraception.2016.04.013","article-title":"Medical abortion reporting of efficacy: the MARE guidelines","volume":"94","author":"Creinin","year":"2016","journal-title":"Contraception"},{"key":"R16-20261118","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R17-20261118","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/sim.2328","article-title":"A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use","volume":"25","author":"Austin","year":"2006","journal-title":"Stat Med"},{"key":"R18-20261118","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-based direct adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J Am Statistician"},{"key":"R19-20261118","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"R20-20261118","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/sim.3782","article-title":"Improving propensity score weighting using machine learning","volume":"29","author":"Lee","year":"2010","journal-title":"Stat Med"},{"key":"R21-20261118","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc"},{"key":"R22-20261118","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/aje\/kwh221","article-title":"Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies","volume":"160","author":"Greenland","year":"2004","journal-title":"Am J Epidemiol"},{"key":"R23-20261118","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.contraception.2012.06.011","article-title":"First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review","volume":"87","author":"Raymond","year":"2013","journal-title":"Contraception"},{"key":"R24-20261118","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/AOG.0b013e3182755763","article-title":"Significant adverse events and outcomes after medical abortion","volume":"121","author":"Cleland","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R25-20261118","article-title":"Barriers to accessing abortion services and perspectives on using mifepristone and misoprostol at home in Great Britain","author":"Aiken","year":"2017","journal-title":"Contraception"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201804000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:01:44Z","timestamp":1795024904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201804000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000002536","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732833128.793553012","asserted-by":"object"}]},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}